English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Guidelines for management of non-small cell lung cancer (NSCLC) strongly recommend  EGFR  mutation testing. These recommendations are particularly relevant in Asians that have higher  EGFR  mutation prevalence. This study aims to explore current testing practices, logistics of testing, types of  EGFR  mutation, and prevalence of  EGFR  mutations in patients with advanced NSCLC in a large comprehensive cancer center in Korea.    Methods  Our retrospective cohort included 1,503 NSCLC patients aged ≥18 years, with stage IIIB/IV disease, who attended the Samsung Medical Center in Seoul, Korea, from January 2007 through July 2010. Trained oncology nurses reviewed and abstracted data from electronic medical records.    Results  This cohort had a mean age (SD) of 59.6 (11.1) years, 62.7% were males, and 52.9% never-smokers. The most common NSCLC histological types were adenocarcinoma (70.5%) and squamous cell carcinoma (18.0%). Overall, 39.5% of patients were tested for  EGFR  mutations. The proportion of patients undergoing EGFR testing during January 2007 through July 2008, August 2008 through September 2009, and October 2009 through July 2010 were 23.3%, 38.3%, and 63.5%, respectively (P<0.001). The median time elapsed between cancer diagnoses and receiving  EGFR  testing results was 21 days.  EGFR  testing was most frequently ordered by oncologists (57.7%), pulmonologists (31.9%), and thoracic surgeons (6.6%).  EGFR  testing was more commonly requested for women, younger patients, stage IV disease, non-smokers, and adenocarcinoma histology. Of 586 cases successfully tested for  EGFR  mutations, 209 (35.7%) were positive, including 118 cases with exon 19 deletions and 62 with L858R mutations.  EGFR  mutation positive patients were more likely to be female, never-smokers, never-drinkers and to have adenocarcinoma.    Conclusions  In a large cancer center in Korea, the proportion of  EGFR  testing increased from 2007 through 2010. The high frequency of  EGFR  mutation positive cases warrants the need for generalized testing in Asian NSCLC patients.

plos one

EGFR Mutation Testing in Patients with Advanced Non-Small Cell Lung Cancer: A Comprehensive Evaluation of Real-World Practice in an East Asian Tertiary Hospital